JP2002543186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002543186A5 JP2002543186A5 JP2000615390A JP2000615390A JP2002543186A5 JP 2002543186 A5 JP2002543186 A5 JP 2002543186A5 JP 2000615390 A JP2000615390 A JP 2000615390A JP 2000615390 A JP2000615390 A JP 2000615390A JP 2002543186 A5 JP2002543186 A5 JP 2002543186A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- phenyl
- hydrogen
- immunodeficiency virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 34
- -1 6 -naphthyl Chemical group 0.000 description 22
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 7
- 229960000311 ritonavir Drugs 0.000 description 7
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 7
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 6
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical group C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 6
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 5
- 229960004748 abacavir Drugs 0.000 description 5
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 5
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 229960000523 zalcitabine Drugs 0.000 description 5
- 229960002555 zidovudine Drugs 0.000 description 5
- 125000006163 5-membered heteroaryl group Chemical class 0.000 description 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229960002656 didanosine Drugs 0.000 description 4
- 229960001627 lamivudine Drugs 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- HINZVVDZPLARRP-YSVIXOAZSA-N (4r,5s,6s,7r)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 HINZVVDZPLARRP-YSVIXOAZSA-N 0.000 description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 3
- ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)-pyrimidin-4-ylamine Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 3
- 229960003205 adefovir dipivoxil Drugs 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 229960001830 amprenavir Drugs 0.000 description 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 229960003804 efavirenz Drugs 0.000 description 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 229960000689 nevirapine Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 229960001852 saquinavir Drugs 0.000 description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960001203 stavudine Drugs 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001624 naphthyl group Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- XUERKRUERHBPBL-UHFFFAOYSA-N 2-chloro-7-hydroxy-10,10-dimethyl-7-phenylpyrido[1,2-a]indole-6,8-dione Chemical compound O=C1N2C3=CC=C(Cl)C=C3C(C)(C)C2=CC(=O)C1(O)C1=CC=CC=C1 XUERKRUERHBPBL-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 0 C*(CC*1)C1=O Chemical compound C*(CC*1)C1=O 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 101150054451 Rtel1 gene Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 229940072253 epivir Drugs 0.000 description 1
- KBEMFSMODRNJHE-JFWOZONXSA-N lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229940087450 zerit Drugs 0.000 description 1
- 229940052255 ziagen Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30518799A | 1999-05-04 | 1999-05-04 | |
| US09/305,187 | 1999-05-04 | ||
| PCT/US2000/011633 WO2000066559A1 (en) | 1999-05-04 | 2000-05-01 | Piperidine derivatives useful as ccr5 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006152916A Division JP2006225407A (ja) | 1999-05-04 | 2006-05-31 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002543186A JP2002543186A (ja) | 2002-12-17 |
| JP2002543186A5 true JP2002543186A5 (enExample) | 2006-07-20 |
| JP3894729B2 JP3894729B2 (ja) | 2007-03-22 |
Family
ID=23179704
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000615390A Expired - Fee Related JP3894729B2 (ja) | 1999-05-04 | 2000-05-01 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2006152916A Withdrawn JP2006225407A (ja) | 1999-05-04 | 2006-05-31 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2011151208A Pending JP2011219493A (ja) | 1999-05-04 | 2011-07-07 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006152916A Withdrawn JP2006225407A (ja) | 1999-05-04 | 2006-05-31 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2011151208A Pending JP2011219493A (ja) | 1999-05-04 | 2011-07-07 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP1659111A3 (enExample) |
| JP (3) | JP3894729B2 (enExample) |
| KR (1) | KR100439357B1 (enExample) |
| CN (2) | CN1151131C (enExample) |
| AR (1) | AR023939A1 (enExample) |
| AT (1) | ATE299866T1 (enExample) |
| AU (2) | AU780983B2 (enExample) |
| BR (1) | BR0010607A (enExample) |
| CA (1) | CA2371587C (enExample) |
| CO (1) | CO5170522A1 (enExample) |
| CZ (1) | CZ301161B6 (enExample) |
| DE (1) | DE60021371T2 (enExample) |
| DK (1) | DK1175402T3 (enExample) |
| EG (1) | EG24533A (enExample) |
| ES (1) | ES2246233T3 (enExample) |
| HK (1) | HK1039330B (enExample) |
| HU (1) | HUP0203528A3 (enExample) |
| IL (1) | IL145742A0 (enExample) |
| MY (1) | MY141473A (enExample) |
| NO (1) | NO322044B1 (enExample) |
| NZ (1) | NZ514675A (enExample) |
| PE (1) | PE20010113A1 (enExample) |
| PL (1) | PL203117B1 (enExample) |
| PT (1) | PT1175402E (enExample) |
| RU (2) | RU2266281C2 (enExample) |
| SA (1) | SA00210270B1 (enExample) |
| SI (1) | SI1175402T1 (enExample) |
| SK (1) | SK286968B6 (enExample) |
| TR (2) | TR200103213T2 (enExample) |
| TW (1) | TWI283666B (enExample) |
| WO (1) | WO2000066559A1 (enExample) |
| ZA (1) | ZA200108867B (enExample) |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
| DK1373256T3 (da) | 2001-03-29 | 2005-10-10 | Schering Corp | CCR5-antagonister, der er nyttige til behandling af AIDS |
| GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| CN1545509A (zh) | 2001-07-02 | 2004-11-10 | 用作趋化因子受体活性调节剂的哌啶衍生物 | |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| AR036882A1 (es) * | 2001-10-15 | 2004-10-13 | Schering Corp | Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales |
| US6818773B2 (en) * | 2001-10-15 | 2004-11-16 | Schering Corporation | Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine |
| JP2005518424A (ja) * | 2001-11-29 | 2005-06-23 | シェーリング コーポレイション | Ａｉｄｓおよび関連するｈｉｖ感染の処置のためのｃｃｒ５−アンタゴニストとしての４（（ｚ）−（４−ブロモフェニル）エトキシイミノ）メチル）−１’−（（２，４−ジメチル−１−オキシド−３−ピリジニルカルボニル）−４’−メチル−１，４’ビピペリジンの薬学的塩の調製 |
| EP2311818B1 (en) | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| CN100396676C (zh) * | 2002-03-29 | 2008-06-25 | 先灵公司 | 作为ccr5拮抗药的哌啶和哌嗪化合物的合成 |
| EP1498125A4 (en) * | 2002-04-24 | 2008-08-20 | Takeda Pharmaceutical | USE OF COMPOUNDS WITH CCR ANTAGONISM |
| WO2004026833A1 (ja) * | 2002-09-20 | 2004-04-01 | Takeda Pharmaceutical Company Limited | 環状アミン化合物、その製造法および用途 |
| JP2004107298A (ja) * | 2002-09-20 | 2004-04-08 | Takeda Chem Ind Ltd | ウレア化合物およびその用途 |
| GB0223223D0 (en) | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
| AU2003300902A1 (en) * | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Piperidine derivatives as CCR5 antagonists |
| PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| TW201018661A (en) | 2003-03-14 | 2010-05-16 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| JPWO2004092136A1 (ja) * | 2003-04-18 | 2006-07-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその用途 |
| EP1619193A4 (en) | 2003-04-18 | 2010-08-11 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| WO2004113323A1 (en) * | 2003-06-13 | 2004-12-29 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
| CA2531059A1 (en) | 2003-07-10 | 2005-01-27 | Schering Corporation | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| US7498346B2 (en) * | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| JP2007522160A (ja) | 2004-02-10 | 2007-08-09 | エフ．ホフマン−ラ ロシュ アーゲー | ケモカインｃｃｒ５受容体モジュレーター |
| SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
| BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| RU2006146608A (ru) | 2004-06-09 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ |
| TWI400232B (zh) * | 2004-09-13 | 2013-07-01 | Ono Pharmaceutical Co | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| EP1844037A1 (en) * | 2005-01-20 | 2007-10-17 | Pfizer Limited | Chemical compounds |
| MX2007009945A (es) * | 2005-02-16 | 2007-09-26 | Schering Corp | Piperazinas sustituidas con heterociclicos con actividad antagonista de cxcr3. |
| CA2598568A1 (en) | 2005-02-23 | 2006-08-31 | Schering Corporation | Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors |
| MX2007010258A (es) * | 2005-02-23 | 2007-09-11 | Schering Corp | Derivados de piperidinil piperazina utiles como inhibidores de receptores de quimiocina. |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20110052612A1 (en) | 2005-05-31 | 2011-03-03 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
| US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
| KR20080037655A (ko) | 2005-07-21 | 2008-04-30 | 아스트라제네카 아베 | 신규 피페리딘 유도체 |
| KR20080056220A (ko) | 2005-10-19 | 2008-06-20 | 에프. 호프만-라 로슈 아게 | 페닐-아세트아마이드 ｎｎｒｔ 저해제 |
| JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Ｉｌ１３に対するヒト抗体および治療的使用 |
| WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| AU2007225836A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| US20090124636A1 (en) * | 2006-04-12 | 2009-05-14 | Pfizer Inc. | Chemical compounds |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| US8618122B2 (en) | 2006-05-16 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
| EP2055705A4 (en) | 2006-07-31 | 2014-08-20 | Ono Pharmaceutical Co | COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF |
| KR101401811B1 (ko) | 2006-08-16 | 2014-05-29 | 에프. 호프만-라 로슈 아게 | 비-뉴클레오사이드 역전사효소 저해제 |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘 |
| RU2469032C2 (ru) | 2006-12-13 | 2012-12-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы |
| CA2673803A1 (en) | 2007-01-10 | 2008-07-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| MX2009010503A (es) | 2007-03-29 | 2009-10-19 | Hoffmann La Roche | Compuestos heterociclicos antiviricos. |
| ES2361595T3 (es) | 2007-05-07 | 2011-06-20 | Novartis Ag | Compuestos orgánicos. |
| KR101578235B1 (ko) | 2007-12-10 | 2015-12-16 | 노파르티스 아게 | 유기 화합물 |
| WO2009111218A2 (en) * | 2008-02-29 | 2009-09-11 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
| TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| CN102573846B (zh) | 2009-08-17 | 2015-10-07 | 因特利凯公司 | 杂环化合物及其用途 |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| KR101491938B1 (ko) | 2010-07-14 | 2015-02-10 | 노파르티스 아게 | Ｉｐ 수용체 효능제 헤테로시클릭 화합물 |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
| EP2755967B1 (en) | 2011-09-16 | 2015-10-21 | Novartis AG | Heterocyclic compounds for the treatment of cystic fibrosis |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| BR112014012056B1 (pt) | 2011-11-18 | 2021-12-14 | Heptares Therapeutics Limited | Compostos agonistas do receptor m1 muscarínico, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou psicótico ou para tratamento ou diminuição da severidade da dor aguda, crônica, neuropática ou inflamatória |
| CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| US9174985B2 (en) | 2012-01-13 | 2015-11-03 | Novartis Ag | Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists |
| US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| EP2802582A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| EP2802585A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pah and related disorders |
| AR089698A1 (es) | 2012-01-13 | 2014-09-10 | Novartis Ag | Compuestos heterociclicos antagonistas del receptor ip |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| CN105189500A (zh) | 2013-02-13 | 2015-12-23 | 诺华股份有限公司 | Ip受体激动剂杂环化合物 |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
| AU2014364735A1 (en) | 2013-12-19 | 2016-07-07 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyl-tetrahydroquinolines |
| EP3083610A1 (de) | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten |
| CN106029648A (zh) * | 2013-12-19 | 2016-10-12 | 拜耳制药股份公司 | 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| JP6404944B2 (ja) | 2014-04-24 | 2018-10-17 | ノバルティス アーゲー | ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体 |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| EA201692140A1 (ru) | 2014-04-24 | 2017-04-28 | Новартис Аг | Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| KR20170036037A (ko) | 2014-07-31 | 2017-03-31 | 노파르티스 아게 | 조합 요법 |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| EP3980121A1 (en) | 2019-06-10 | 2022-04-13 | Novartis AG | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| CN114341132A (zh) | 2019-08-28 | 2022-04-12 | 诺华股份有限公司 | 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| ES2182104T3 (es) * | 1996-07-10 | 2003-03-01 | Schering Corp | Piperidinas 1,4-disustituidas como antagonistas muscarinicos. |
| AU6623796A (en) * | 1996-07-25 | 1998-02-20 | Terence George Mackay | Improvements in or relating to fishing |
| HUP9904363A3 (en) * | 1996-08-15 | 2000-12-28 | Schering Corp | Piperidine ether muscarinic antagonists and pharmaceutical compositions containing them |
| WO1999004794A1 (en) * | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
-
2000
- 2000-05-01 PT PT00926487T patent/PT1175402E/pt unknown
- 2000-05-01 TR TR2001/03213T patent/TR200103213T2/xx unknown
- 2000-05-01 EP EP05010590A patent/EP1659111A3/en not_active Withdrawn
- 2000-05-01 TR TR2004/02496T patent/TR200402496T2/xx unknown
- 2000-05-01 HK HK02100825.9A patent/HK1039330B/en not_active IP Right Cessation
- 2000-05-01 CN CNB008071683A patent/CN1151131C/zh not_active Expired - Fee Related
- 2000-05-01 DK DK00926487T patent/DK1175402T3/da active
- 2000-05-01 CA CA002371587A patent/CA2371587C/en not_active Expired - Fee Related
- 2000-05-01 AT AT00926487T patent/ATE299866T1/de not_active IP Right Cessation
- 2000-05-01 WO PCT/US2000/011633 patent/WO2000066559A1/en not_active Ceased
- 2000-05-01 NZ NZ514675A patent/NZ514675A/en not_active IP Right Cessation
- 2000-05-01 PL PL351412A patent/PL203117B1/pl not_active IP Right Cessation
- 2000-05-01 ES ES00926487T patent/ES2246233T3/es not_active Expired - Lifetime
- 2000-05-01 CZ CZ20013941A patent/CZ301161B6/cs not_active IP Right Cessation
- 2000-05-01 EP EP00926487A patent/EP1175402B1/en not_active Expired - Lifetime
- 2000-05-01 SI SI200030719T patent/SI1175402T1/xx unknown
- 2000-05-01 RU RU2001132635/04A patent/RU2266281C2/ru not_active IP Right Cessation
- 2000-05-01 SK SK1567-2001A patent/SK286968B6/sk not_active IP Right Cessation
- 2000-05-01 JP JP2000615390A patent/JP3894729B2/ja not_active Expired - Fee Related
- 2000-05-01 BR BR0010607-0A patent/BR0010607A/pt not_active Application Discontinuation
- 2000-05-01 IL IL14574200A patent/IL145742A0/xx unknown
- 2000-05-01 DE DE60021371T patent/DE60021371T2/de not_active Expired - Lifetime
- 2000-05-01 HU HU0203528A patent/HUP0203528A3/hu unknown
- 2000-05-01 KR KR10-2001-7013862A patent/KR100439357B1/ko not_active Expired - Fee Related
- 2000-05-01 AU AU45010/00A patent/AU780983B2/en not_active Ceased
- 2000-05-01 CN CNA2004100282860A patent/CN1524527A/zh active Pending
- 2000-05-02 EG EG20000563A patent/EG24533A/xx active
- 2000-05-02 PE PE2000000406A patent/PE20010113A1/es not_active Application Discontinuation
- 2000-05-02 CO CO00031252A patent/CO5170522A1/es not_active Application Discontinuation
- 2000-05-02 MY MYPI20001891A patent/MY141473A/en unknown
- 2000-05-02 AR ARP000102095A patent/AR023939A1/es unknown
- 2000-05-02 TW TW089108325A patent/TWI283666B/zh active
- 2000-08-05 SA SA00210270A patent/SA00210270B1/ar unknown
-
2001
- 2001-10-26 ZA ZA200108867A patent/ZA200108867B/xx unknown
- 2001-11-02 NO NO20015365A patent/NO322044B1/no not_active IP Right Cessation
-
2005
- 2005-05-31 AU AU2005202358A patent/AU2005202358B2/en not_active Ceased
- 2005-06-23 RU RU2005120376/15A patent/RU2005120376A/ru not_active Application Discontinuation
-
2006
- 2006-05-31 JP JP2006152916A patent/JP2006225407A/ja not_active Withdrawn
-
2011
- 2011-07-07 JP JP2011151208A patent/JP2011219493A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002543186A5 (enExample) | ||
| KR100613528B1 (ko) | Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 | |
| JP3894729B2 (ja) | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 | |
| JP2004525157A5 (enExample) | ||
| AU2002255947A1 (en) | CCR5 antagonists useful for treating AIDS | |
| KR20040029057A (ko) | Ｃｃｒ5 길항제로서 유용한 피페리딘 유도체 | |
| CA2716838A1 (en) | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same | |
| CA2442210C (en) | Aryl oxime-piperazines useful as ccr5 antagonists | |
| AU2002303168A1 (en) | Aryl oxime-piperazines useful as ccr5 antagonists | |
| HK1057363B (en) | Ccr5 antagonists useful for treating aids | |
| HK1057211B (en) | Aryl oxime-piperazines useful as ccr5 antagonists | |
| HK1083505B (en) | Ccr5 antagonists useful for treating aids |